Katwin 12 Tablet contains Deflazacort 12 mg, a synthetic glucocorticoid used for its potent anti-inflammatory and immunosuppressive properties. It is indicated for the management of various inflammatory and autoimmune conditions, including corticosteroid-responsive disorders such as rheumatoid arthritis, systemic lupus erythematosus, allergic reactions, and certain muscular dystrophies. Deflazacort modulates the immune response by inhibiting the release of inflammatory mediators and suppressing the activity of immune cells, thereby reducing inflammation and tissue damage. Katwin 12 is administered orally, with dosage tailored according to the severity of the condition and patient response. It is essential to follow medical advice strictly to minimize potential adverse effects, which may include hyperglycemia, osteoporosis, increased susceptibility to infections, and adrenal suppression upon prolonged use. Gradual tapering is recommended to prevent withdrawal symptoms and adrenal insufficiency. Caution is advised in patients with diabetes, hypertension, peptic ulcers, and psychiatric disorders. Regular monitoring of blood pressure, blood glucose, and bone density is advisable during long-term therapy. Katwin 12 should be used under strict medical supervision to ensure optimal therapeutic outcomes while minimizing risks associated with corticosteroid therapy.